|
Distinguished Faculty
- Dr. Vahri Beaumont, Senior Research Biologist, Automated
Imaging and Electrophysiology, Merck Sharp and Dohme
- Dr. Gerd Binnig, Professor, University of Munich
- Dr. John Bixby, Professor, Pharmacology/Miami Project,University of Miami Miller School of Medicine
- Dr. Anne E. Carpenter, Novartis Fellow of the Life Sciences
Research Foundation, Sabatini Laboratory, Whitehead Institute for Biomedical Research
- Dr. John Dunlop, Director, Discovery Neuroscience, Wyeth
Research
- Mrs. Judy Dziuba, Senior Scientist, Lead Discovery, Bayer
Healthcare AG
- Dr. Yan Feng, Lab Head, Genome and Proteome Sciences,
Novartis Institute for BioMedical Research
- Mr. Ross Francis, Senior Scientist, Target Discovery,
Exelixis, Inc.
- Mr. David F. Gebhard, Principal Scientist, Lead Assessment
Team, Pfizer, Inc.
- Dr. Dorothea Haasen, Research Scientist, Integrated Lead
Discovery, Boehringer Ingelheim Pharma GmbH&Co. KG
- Dr. Ralf Heilker, Senior Scientist, Integrated Lead
Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG
- Dr. Bonnie Howell, Senior Research Biochemist, Cancer
Research, Merck & Co., Inc.
- Dr. Paul Johnston, Research Associate Professor,
Pharmacology, University of Pittsburgh School of Medicine
- Dr. Eberhard Krausz, HT-Technology Development Studio,
Max Planck Institute of Molecular Cell Biology and Genetics
(MPI-CBG)
- Mr. Aidas Kriauciunas, Research Scientist, Integrative
Biology, Eli Lilly and Company
- Dr. Jonathan Lee, Research Advisor, Lead Generation and
Optimization Biology, Eli Lilly and Company
- Dr. Fred Maxfield, Professor and Chairman, Department of
Biochemistry, Weill Medical College of Cornell University
- Dr. Robert F. Murphy, Professor, Departments of Biological
Sciences and Biomedical Engineering, Carnegie Mellon University
- Dr. Anthony Nichols, Head of Screening Technology
Development, Molecular Screening & Cellular Pharmacology, Serono Pharmaceutical Research Institute
- Dr. Peter O’Brien, Head of Discovery Toxicology
Biomarkers, Safety Sciences, Europe, Pfizer Limited
- Dr. Petra Perner, Director, Institute of Computer Vision and
Applied Computer Sciences, Germany
- Dr. Oliver Poeschke, Scientist, Central Assay Development
& Screening, Merck KGaA
- Dr. Stefan Prechtl, HCA Group Leader, Enabling
Technologies, AD-HTS, Schering AG
- Dr. Daniel R. Rines, Institute Fellow, Lead Discovery,
Genomics Institute of the Novartis Research Foundation
(GNF)
- Dr. Paul Sammak, Associate Professor, Pittsburgh
Development Center at the Magee Women’s Research Institute, Department of Obstetrics, Gynecology and
Reproductive Sciences, University of Pittsburg
- Dr. Mark Schurdak, Group Leader, Biological Screening,
Abbott Laboratories
- Dr. Orian Shirihai, Professor, Pharmacology, Tufts
University Medical School
- Mrs. Marjo Simonen, Discovery Technologies, Novartis
Pharma AG
- Dr. Louis Stancato, Principal Research Scientist, Cancer
Growth and Translational Genetics, Eli Lilly and Company,
Lilly Corporate Center
- Mr. Oscar Trask, Associate in Research, Center for Drug
Discovery, Duke University Medical Center
- Dr. Mark Uhlik, Research Scientist, Angiogenesis and
Tumor Microenvironment DHT, Eli Lilly & Co.
- Dr. Andreas Vogt, Research Assistant Professor,
Pharmacology, University of Pittsburgh
- Dr. Zhong Zhong, VP, Drug Discovery Technologies,
Cell & Molecular Technologies, Inc.
|
|
